Results 1 to 10 of about 338,912 (243)

Loss-of-function polymorphism in IL6R reduces risk of JAK2V617F somatic mutation and myeloproliferative neoplasm: A Mendelian randomization study

EClinicalMedicine, 2020
Background: Whether inflammation is independently associated with development of JAK2V617F mutation and myeloproliferative neoplasm is not clear. We tested the hypothesis that a loss-of-function polymorphism in IL6R (marked by rs4537545) reduces risk of ...
Kasper Mønsted Pedersen, Yunus Çolak, Christina Ellervik, Hans Carl Hasselbalch, Stig E. Bojesen, Børge G. Nordestgaard   +5 more
openalex   +3 more sources

JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate

Haematologica, 2014
Clinical significance of the JAK2V617F mutation in patients with a myeloproliferative neoplasm has been the target of intensive research in recent years. However, there is considerably uncertainty about prognosis in JAK2V617F positive individuals without
Camilla Friis Bryde Nielsen, Stig E. Bojesen, Børge G. Nordestgaard, Klaus F. Kofoed, Henrik Birgens   +4 more
openalex   +4 more sources

Histopathology imagery dataset of Ph-negative myeloproliferative neoplasm. [PDF]

Data Brief, 2023
Tumorous cancer has been a widely known and well-studied medical phenomenon; however, rare diseases like Myeloproliferative Neoplasm (MPN) have received less attention, leading to delayed diagnosis.
Mohamad Yusof UK, Mashohor S, Hanafi M, Md Noor S, Zainal N.   +4 more
europepmc   +2 more sources

Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency

Haematologica, 2016
Juvenile myelomonocytic leukemia is a rare myeloproliferative neoplasm characterized by hyperactive RAS signaling. Neurofibromin1 (encoded by the NF1 gene) is a negative regulator of RAS activation.
Z. Sachs, R. A. Been, Krista J. DeCoursin, Hanh T. Nguyen, N. A. Mohd Hassan, Klara E Noble-Orcutt, C. Eckfeldt, E. Pomeroy, E. Diaz-Flores, Jennifer L. Geurts, Miechaleen D. Diers, D. Hasz, K. Morgan, M. MacMillan, K. Shannon, D. Largaespada, S. Wiesner   +16 more
semanticscholar   +3 more sources

Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea [PDF]

Journal of Korean medical science, 2016
The nationwide statistical analysis of each disease of classical myeloproliferative neoplasm (MPN) in Korea has not been reported yet. To this end, we have analyzed incidence rates, survival rates and treatment pattern of polycythemia vera (PV), primary ...
Yoojoo Lim, Jeong‐Ok Lee, Soo‐Mee Bang   +2 more
openalex   +2 more sources

Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm

Blood Cancer Journal, 2023
Leukemic transformation in myeloproliferative neoplasms (MPN), also referred to as “blast-phase MPN”, is the most feared disease complication, with incidence estimates of 1–4% for essential thrombocythemia, 3–7% for polycythemia vera, and 9–13% for ...
A. Tefferi, H. Alkhateeb, N. Gangat
semanticscholar   +1 more source

Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management

American journal of hematology/oncology, 2023
Atypical chronic myeloid leukemia (aCML) and myelodysplastic/myeloproliferative (MDS/MPN) neoplasms, not otherwise specified (NOS), are MDS/MPN overlap neoplasms characterized by leukocytosis, in the absence of monocytosis and eosinophilia, with
M. Patnaik, A. Tefferi
semanticscholar   +1 more source

Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm

Nature Communications, 2022
Interleukin-1β (IL-1β) is a master regulator of inflammation. Increased activity of IL-1β has been implicated in various pathological conditions including myeloproliferative neoplasms (MPNs).
S. Rai, Élodie Grockowiak, N. Hansen, Damien Luque Paz, Cédric B. Stoll, Hao Hui, Gabriele Mild-Schneider, S. Dirnhofer, C. Farady, S. Méndez-Ferrer, R. Skoda   +10 more
semanticscholar   +1 more source

Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm

Nature Communications, 2022
Chronic inflammation is frequently associated with myeloproliferative neoplasms (MPN), but the role of inflammation in the pathogenesis of MPN remains unclear.
Mohammed Ferdous-Ur Rahman, Yue Yang, Bao T. Le, Avik Dutta, Julia Posyniak, P. Faughnan, Mohammad A Sayem, N. Aguilera, G. Mohi   +8 more
semanticscholar   +1 more source

Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases

American journal of hematology/oncology, 2021
Venetoclax (Ven) combined with a hypomethylating agent (HMA) has now emerged as an effective treatment regimen for acute myeloid leukemia, in both de novo and relapsed/refractory setting.
N. Gangat, P. Guglielmelli, N. Szuber, K. Begna, M. Patnaik, M. Litzow, A. Al-Kali, J. Foran, J. Palmer, H. Alkhateeb, M. Elliott, C. Hanson, A. Pardanani, F. Mannelli, A. Vannucchi, A. Tefferi   +15 more
semanticscholar   +1 more source